Epigenetics Drugs and Diagnostic Technologies Market

Epigenetics Drugs and Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat, and Romidepsin) and Others) and Epigenetics Diagnostic Technologies (DNAMethylation and CHIP Technology) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030


Gene mutations often result in the disruption of normal processing of genes and leads to the development of diseases. However, recently discovered epigenetic alterations have shown the potential to greatly influence tumoral response to therapy regimens. Such epigenetic alterations have proven to be dynamic, and thus could be restored. Due to their reversible nature, the promising opportunity to improve chemotherapy response using epigenetic therapy has arisen. Potential epidrug candidates can be found through a process known as drug repositioning or repurposing, a promising strategy for the discovery of novel potential targets in already approved drugs. At present, novel epidrug candidates have been identified in preclinical studies and some others are currently being tested in clinical trials, ready to be repositioned. The main focus of epidrug repurposing is the development of agents with one indication only, while giving patients lower cost therapies and a novel precision medical approach to optimize treatment efficacy and reduce toxicity. Epigenetic drugs are commonly used in the treatment of infections, cancer, diabetic retinopathy, cardiac dysfunction, schizophrenia, and mental problems including posttraumatic stress disorder. They are categorized into four classes: hydroxamates (vorinostat, belinostat, panobinostat), benzamides (entinostat, chidamide), cyclic peptides (romidepsin), and aliphatic acids.

Market Dynamics

Increasing new product launches, and mergers and acquisitions by key market players is expected to drive the global epigenetics drugs & diagnostic technologies market growth. For instance, on November 4, 2021, Epizyme, Inc., a U.S. based clinical-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to EZM0414, the company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). The company has also initiated a Phase 1/1b study to evaluate safety and determine the optimal dose of EZM0414.

Key features of the study:
  • This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market
Detailed Segmentation:
  • Global Epigenetics Drugs and Diagnostic Technologies Market, By Type:
  • Epigenetic Drugs
  • DNMT Inhibitors
  • Azacitidine
  • Decitabine
  • HDAC Inhibitors
  • Vorinostat
  • Romidepsin
  • Others
  • Epigenetics Diagnostic Technologies
  • DNAMethylation
  • CHIP Technology
  • Global Epigenetics Drugs and Diagnostic Technologies Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Regenacy Pharmaceuticals, Inc.
  • Astex Pharmaceuticals
  • 4SC AG
  • CellCentric Ltd.
  • Celleron Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • Oryzon Genomics S.A.
  • ChromaMedicine, Inc.
  • Epizyme, Inc.
  • EpiGentek Group Inc.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Type
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
4. Global Epigenetic Drugs & Diagnostic Technologies Market – COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2018–2030, (US$ Billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019-2030
Segment Trends
Epigenetic Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
DNMT Inhibitors
Azacitidine
Decitabine
HDAC Inhibitors
Vorinostat
Romidepsin
Others
Epigenetics Diagnostic Technologies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
DNAMethylation
CHIP Technology
6. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2018–2030, (US$ Billion)
Introduction
Market Share Analysis, By Region, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Region, 2019-2030
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2018 - 2030, (US$ Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018–2030, (US$ Billion)
North Africa
Central Africa
South Africa
7. Competitive Landscape
Regenacy Pharmaceuticals, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Astex Pharmaceuticals
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
4SC AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
CellCentric Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Celleron Therapeutics Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Oryzon Genomics S.A.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
ChromaMedicine, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Epizyme, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
EpiGentek Group Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
8. Section
Research Methodology
About Us
*Browse 21 market data tables and 20 figures on “Epigenetic Drugs & Diagnostic Technologies Market” - Global forecast to 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings